236O Olaparib (ola) plus bevacizumab (bev) as maintenance (mx) therapy in patients (pts) with newly diagnosed advanced ovarian carcinoma (OC): Japan subset of the PAOLA-1 trial
Keiichi Fujiwara(Saitama Medical University), Isabelle Laure Ray-Coquard(Université Claude Bernard Lyon 1), Takashi Matsumoto(Aso Iizuka Hospital), Hugues Bourgeois(Barwon Health), Kan Yonemori(National Cancer Centre Japan), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), Hiroaki Kobayashi(Kyushu University), Alexander Reinthaller(Medical University of Vienna), Shoji Nagao(Saitama Medical University), Éric Pujade-Lauraine(Eau de Paris (France)), Philipp Harter(Kliniken Essen-Mitte), Ralph Bloomfield(AstraZeneca (United Kingdom)), Toyomi Satoh(University of Tsukuba), Tomoko Fujita(AstraZeneca (Japan)), Hiroyuki Fujiwara(Jichi Medical University), Isabel Palacio(Universidad de Antioquia), Hiroyuki Yoshida(University of Chicago)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Certolizumab Pegol for the Treatment of Crohn's Disease
|New England Journal of Medicine|2007|1.1k
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
|New England Journal of Medicine|2007|1.1k